In a landmark decision, the U.S. Food and Drug Administration has granted approval for Novo Nordisk to update the labeling of its popular weight loss drug Wegovy.
The medication can now be marketed as the first obesity treatment that reduces the risk of major cardiovascular events like heart attacks, strokes, and cardiovascular deaths in obese or overweight people.
